Ketrel Xr

Quetiapine, the active ingredient in Ketrel Xr, is an atypical antipsychotic presented as an oral tablet for oral use. It is prescribed to manage symptoms of schizophrenia, bipolar disorder, and as adjunct therapy in major depressive disorder. The drug modulates neurotransmitter activity at multiple receptors, helping to alleviate psychotic and mood disturbances.

GNH USA supplies Ketrel Xr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with capabilities for bulk manufacturing, quality assurance, and regulatory support across EU and global markets.

Quetiapine is an atypical antipsychotic that acts on multiple neurotransmitter pathways, providing therapeutic benefit in several psychiatric conditions.

- Schizophrenia: reduces positive and negative symptoms, improving overall functioning. - Bipolar disorder: stabilizes mood during manic and depressive episodes, decreasing relapse risk. - Major depressive disorder (adjunct): enhances antidepressant response when added to standard therapy.

Quetiapine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Dry mouth: decreased salivation causing oral discomfort. - Constipation: infrequent bowel movements or hard stools. - Weight gain: increase in body weight over time.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare life‑threatening reaction with fever, rigidity, autonomic instability. - Tardive dyskinesia: persistent involuntary movements, especially of the face and tongue. - Orthostatic hypotension: sudden drop in blood pressure upon standing, leading to dizziness or fainting.

When prescribing quetiapine, clinicians should consider several safety precautions to minimize risk. - Monitor metabolic parameters: regularly assess weight, glucose, and lipid levels. - Assess cardiovascular status: watch for orthostatic hypotension and QT prolongation. - Use caution in elderly: increased sensitivity to sedation and falls, especially with dementia‑related psychosis. - Avoid abrupt discontinuation: taper dose gradually to reduce withdrawal or rebound symptoms. - Pregnancy and lactation: limited data; evaluate risk‑benefit before use. - Store at room temperature: keep in original container, protect from moisture and light.

Quetiapine can interact with other medicines, altering its plasma concentration or enhancing pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase quetiapine levels, raising toxicity risk. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can substantially lower quetiapine concentrations, reducing efficacy.

Moderate Interactions (Monitor Closely): - CNS depressants (alcohol, benzodiazepines, opioids): additive sedation and respiratory depression. - Antihypertensive agents: enhanced hypotensive effect, especially orthostatic changes. - Other antipsychotics or serotonergic drugs: increased risk of QT prolongation and cardiac arrhythmias.